EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Rumona Dickson; Angela Boland; Rui Duarte; Eleanor Kotas; Nerys Woolacott; Robert Hodgson; Rob Riemsma; Sabine Grimm; Bram Ramaekers; Manuela Joore; Nasuh Büyükkaramikli; Eva Kaltenthaler; Matt Stevenson; Abdullah Pandor; Steve Edwards; Martin Hoyle; Jonathan Shepherd; Xavier Armoiry; Miriam Brazzelli

doi:10.1007/s40258-018-0393-7

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Rumona Dickson (Corresponding Author), Angela Boland, Rui Duarte, Eleanor Kotas, Nerys Woolacott, Robert Hodgson, Rob Riemsma, Sabine Grimm, Bram Ramaekers, Manuela Joore, Nasuh Büyükkaramikli, Eva Kaltenthaler, Matt Stevenson, Abdullah Pandor, Steve Edwards, Martin Hoyle, Jonathan Shepherd, Xavier Armoiry, Miriam Brazzelli

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

8 Downloads (Pure)

Original language	English
Pages (from-to)	429-432
Number of pages	4
Journal	Applied Health Economics and Health Policy
Volume	16
Issue number	4
Early online date	28 May 2018
DOIs	https://doi.org/10.1007/s40258-018-0393-7
Publication status	Published - Aug 2018

Bibliographical note

The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA Programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the UK Department of Health and the NIHR.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40258-018-0393-7Licence: CC BY

EMA and NICE Appraisal Processes for Cancer Drugs
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Final published version, 409 KBLicence: CC BY

Cite this

Dickson, R., Boland, A., Duarte, R., Kotas, E., Woolacott, N., Hodgson, R., Riemsma, R., Grimm, S., Ramaekers, B., Joore, M., Büyükkaramikli, N., Kaltenthaler, E., Stevenson, M., Pandor, A., Edwards, S., Hoyle, M., Shepherd, J., Armoiry, X., & Brazzelli, M. (2018). EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Applied Health Economics and Health Policy, 16(4), 429-432. https://doi.org/10.1007/s40258-018-0393-7

Dickson, R, Boland, A, Duarte, R, Kotas, E, Woolacott, N, Hodgson, R, Riemsma, R, Grimm, S, Ramaekers, B, Joore, M, Büyükkaramikli, N, Kaltenthaler, E, Stevenson, M, Pandor, A, Edwards, S, Hoyle, M, Shepherd, J, Armoiry, X & Brazzelli, M 2018, 'EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties', Applied Health Economics and Health Policy, vol. 16, no. 4, pp. 429-432. https://doi.org/10.1007/s40258-018-0393-7

@article{673e322a75b84c4e8dbfb9da5c88a148,

title = "EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties",

author = "Rumona Dickson and Angela Boland and Rui Duarte and Eleanor Kotas and Nerys Woolacott and Robert Hodgson and Rob Riemsma and Sabine Grimm and Bram Ramaekers and Manuela Joore and Nasuh B{\"u}y{\"u}kkaramikli and Eva Kaltenthaler and Matt Stevenson and Abdullah Pandor and Steve Edwards and Martin Hoyle and Jonathan Shepherd and Xavier Armoiry and Miriam Brazzelli",

note = "The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA Programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the UK Department of Health and the NIHR.",

year = "2018",

month = aug,

doi = "10.1007/s40258-018-0393-7",

language = "English",

volume = "16",

pages = "429--432",

journal = "Applied Health Economics and Health Policy",

issn = "1175-5652",

publisher = "Adis International Ltd",

number = "4",

}

TY - JOUR

T1 - EMA and NICE Appraisal Processes for Cancer Drugs

T2 - Current Status and Uncertainties

AU - Dickson, Rumona

AU - Boland, Angela

AU - Duarte, Rui

AU - Kotas, Eleanor

AU - Woolacott, Nerys

AU - Hodgson, Robert

AU - Riemsma, Rob

AU - Grimm, Sabine

AU - Ramaekers, Bram

AU - Joore, Manuela

AU - Büyükkaramikli, Nasuh

AU - Kaltenthaler, Eva

AU - Stevenson, Matt

AU - Pandor, Abdullah

AU - Edwards, Steve

AU - Hoyle, Martin

AU - Shepherd, Jonathan

AU - Armoiry, Xavier

AU - Brazzelli, Miriam

N1 - The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA Programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the UK Department of Health and the NIHR.

PY - 2018/8

Y1 - 2018/8

U2 - 10.1007/s40258-018-0393-7

DO - 10.1007/s40258-018-0393-7

M3 - Article

C2 - 29808296

SN - 1175-5652

VL - 16

SP - 429

EP - 432

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

IS - 4

ER -